Vanguard Portfolio Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Vanguard Portfolio Management's CRL Position: Q3 2026 in Review
Vanguard Portfolio Management reduced its Charles River Laboratories (CRL) stake by 0.99% in Q3 2026, selling an estimated $5.75M and leaving 2,189,157 shares worth $646M. The position accounts for 0.03% of the portfolio, ranked #568.
Vanguard Portfolio Management first reported a position in CRL in Q1 2026 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Vanguard Portfolio Management held 2,189,157 shares of Charles River Laboratories worth $646M as of Q3 2026.
- Vanguard Portfolio Management sold 21,822 Charles River Laboratories shares in Q3 2026, an estimated $5.75M.
- Charles River Laboratories made up 0.03% of Vanguard Portfolio Management's portfolio in Q3 2026, its #568 holding.
- Vanguard Portfolio Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 3 quarters since.
- 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.